OBJECTIVE: The onset of new conduction abnormalities requiring permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) is still a relevant adverse event. The main objective of this registry was to identify modifiable procedural risk factors for an improved outcome (lower rate of PPI) after TAVI in patients at high risk of PPI. METHODS: Patients from four European centres receiving a balloon-expandable TAVI (Edwards SAPIEN 3/3 Ultra) and considered at high risk of PPI (pre-existing conduction disturbance, heavily calcified left ventricular outflow tract or short membranous septum) were prospectively enrolled into registry. RESULTS: A total of 300 patients were included: 42 (14.0%) required PPI after TAVI and 258 (86.0%) did not. Patients with PPI had a longer intensive care unit plus intermediate care stay (65.7 vs 16.3 hours, p<0.001), general ward care stay (6.9 vs 5.3 days, p=0.004) and later discharge (8.6 vs 5.0 days, p<0.001). Of the baseline variables, only pre-existing right bundle branch block at baseline (OR 6.8, 95% CI 2.5 to 18.1) was significantly associated with PPI in the multivariable analysis. Among procedure-related variables, oversizing had the highest impact on the rate of PPI: higher than manufacturer-recommended sizing, mean area oversizing as well as the use of the 29 mm valve (OR 3.4, 95% CI 1.4 to 8.5, p=0.008) all were significantly associated with PPI. Rates were higher with the SAPIEN 3 (16.1%) vs SAPIEN 3 Ultra (8.5%), although not statistically significant but potentially associated with valve sizing. Implantation depth and postdelivery balloon dilatation also tended to affect PPI rates but without a statistical significance. CONCLUSION: Valve oversizing is a strong procedure-related risk factor for PPI following TAVI. The clinical impact of the valve type (SAPIEN 3), implantation depth, and postdelivery balloon dilatation did not reach significance and may reflect already refined procedures in the participating centres, giving attention to these avoidable risk factors. TRIAL REGISTRATION NUMBER: NCT03497611.

Clinic for General and Interventional Cardiology Angiology Ruhr University Bochum Bochum Germany

Department of Cardiology and Angiology University Hospital Tübingen Tubingen Baden Württemberg Germany

Department of Cardiology Cologne University Cologne Germany

Department of Cardiology Linköping University Hospital Linköping Sweden

Edwards Lifesciences Prague Czech Republic

Heart Center University of Amsterdam Amsterdam Noord Holland The Netherlands

Institute for Pharmacology and Preventive Medicine Cloppenburg Germany

See more in PubMed

Carnero-Alcázar M, Maroto LC, Cobiella-Carnicer J, et al. . Transcatheter versus surgical aortic valve replacement in moderate and high-risk patients: a meta-analysis. Eur J Cardiothorac Surg 2017;51:644–52. 10.1093/ejcts/ezw388 PubMed DOI

Leon MB, Smith CR, Mack M, et al. . Transcatheter aortic-valve implantation for aortic stenosis in patients who can not undergo surgery. N Engl J Med 2010;363:1597–607. 10.1056/NEJMoa1008232 PubMed DOI

Leon MB, Smith CR, Mack MJ, et al. . Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609–20. 10.1056/NEJMoa1514616 PubMed DOI

Muller Moran HR, Eikelboom R, Lodewyks C, et al. . Two-Year outcomes from the partner 3 trial: where do we stand? Curr Opin Cardiol 2021;36:141–7. 10.1097/HCO.0000000000000813 PubMed DOI

Smith CR, Leon MB, Mack MJ, et al. . Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187–98. 10.1056/NEJMoa1103510 PubMed DOI

Vahanian A, Beyersdorf F, Praz F, et al. . 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561–632. 10.1093/eurheartj/ehab395 PubMed DOI

Seeger J, Gonska B, Rottbauer W, et al. . New generation devices for Transfemoral transcatheter aortic valve replacement are superior compared with last generation devices with respect to VARC-2 outcome. Cardiovasc Interv Ther 2018;33:247–55. 10.1007/s12928-017-0477-6 PubMed DOI

Nazif TM, Dizon JM, Hahn RT, et al. . Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the partner (placement of aortic transcatheter valves) trial and registry. JACC Cardiovasc Interv 2015;8:60–9. 10.1016/j.jcin.2014.07.022 PubMed DOI

Tarantini G, Mojoli M, Purita P, et al. . Unravelling the (arte)fact of increased pacemaker rate with the edwards SAPIEN 3 valve. EuroIntervention 2015;11:343–50. 10.4244/EIJY14M11_06 PubMed DOI

Fujita B, Kütting M, Seiffert M, et al. . Calcium distribution patterns of the aortic valve as a risk factor for the need of permanent pacemaker implantation after transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging 2016;17:1385–93. 10.1093/ehjci/jev343 PubMed DOI

Husser O, Pellegrini C, Kessler T, et al. . Predictors of permanent pacemaker implantations and new-onset conduction abnormalities with the SAPIEN 3 balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv 2016;9:244–54. 10.1016/j.jcin.2015.09.036 PubMed DOI

De Torres-Alba F, Kaleschke G, Diller GP, et al. . Changes in the pacemaker rate after transition from edwards SAPIEN XT to SAPIEN 3 transcatheter aortic valve implantation: the critical role of valve implantation height. JACC Cardiovasc Interv 2016;9:805–13. 10.1016/j.jcin.2015.12.023 PubMed DOI

Schwerg M, Fulde F, Dreger H, et al. . Optimized implantation height of the Edwards SAPIEN 3 valve to minimize pacemaker implantation after TAVI. J Interv Cardiol 2016;29:370–4. 10.1111/joic.12302 PubMed DOI

Mauri V, Reimann A, Stern D, et al. . Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv 2016;9:2200–9. 10.1016/j.jcin.2016.08.034 PubMed DOI

Gonska B, Seeger J, Keßler M, et al. . Predictors for permanent pacemaker implantation in patients undergoing Transfemoral aortic valve implantation with the Edwards sapien 3 valve. Clin Res Cardiol 2017;106:590–7. 10.1007/s00392-017-1093-2 PubMed DOI

Maeno Y, Abramowitz Y, Kawamori H, et al. . A highly predictive risk model for pacemaker implantation after TAVR. JACC Cardiovasc Imaging 2017;10:1139–47. 10.1016/j.jcmg.2016.11.020 PubMed DOI

Bisson A, Bodin A, Herbert J, et al. . Pacemaker implantation after balloon- or self-expandable transcatheter aortic valve replacement in patients with aortic stenosis. J Am Heart Assoc 2020;9:e015896. 10.1161/JAHA.120.015896 PubMed DOI PMC

Droppa M, Rudolph TK, Baan J, et al. . Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesis. Heart Vessels 2020;35:1735–45. 10.1007/s00380-020-01653-6 PubMed DOI

van Rosendael PJ, Delgado V, Bax JJ. Pacemaker implantation rate after transcatheter aortic valve implantation with early and new-generation devices: a systematic review. Eur Heart J 2018;39:2003–13. 10.1093/eurheartj/ehx785 PubMed DOI

Siontis GCM, Jüni P, Pilgrim T, et al. . Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol 2014;64:129–40. 10.1016/j.jacc.2014.04.033 PubMed DOI

Xiao F, Yang J, Fan R. Effects of COPD on in-hospital outcomes of transcatheter aortic valve implantation: results from the National inpatient sample database. Clin Cardiol 2020;43:1524–33. 10.1002/clc.23475 PubMed DOI PMC

Liao YB, He ZX, Zhao ZG, et al. . The relationship between chronic obstructive pulmonary disease and transcatheter aortic valve implantation -- a systematic review and meta-analysis. Catheter Cardiovasc Interv 2016;87 Suppl 1:570–8. 10.1002/ccd.26443 PubMed DOI

Luçon A, Oger E, Bedossa M, et al. . Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the France 2 registry. Circ Cardiovasc Interv 2014;7:240–7. 10.1161/CIRCINTERVENTIONS.113.000482 PubMed DOI

Ancona MB, Moroni F, Pagnesi M, et al. . Impact of left ventricular outflow tract calcification on pacemaker implantation after transcatheter aortic valve implantation with second-generation devices. J Invasive Cardiol 2020;32:180–5. PubMed

Becker M, Blangy H, Folliguet T, et al. . Incidence, indications and predicting factors of permanent pacemaker implantation after transcatheter aortic valve implantation: a retrospective study. Arch Cardiovasc Dis 2017;110:508–16. 10.1016/j.acvd.2017.03.004 PubMed DOI

Ullah W, Zahid S, Zaidi SR, et al. . Predictors of permanent pacemaker implantation in patients undergoing transcatheter aortic valve replacement - a systematic review and meta-analysis. J Am Heart Assoc 2021;10:e020906. 10.1161/JAHA.121.020906 PubMed DOI PMC

Pellegrini C, Kim W-K, Holzamer A, et al. . Multicenter evaluation of prosthesis oversizing of the SAPIEN 3 transcatheter heart valve. impact on device failure and new pacemaker implantations. Rev Esp Cardiol (Engl Ed) 2019;72:641–8. 10.1016/j.rec.2018.06.005 PubMed DOI

Leber AW, Eichinger W, Rieber J, et al. . MSCT guided sizing of the edwards sapien XT TAVI device: impact of different degrees of oversizing on clinical outcome. Int J Cardiol 2013;168:2658–64. 10.1016/j.ijcard.2013.03.030 PubMed DOI

Binder RK, Rodés-Cabau J, Wood DA, et al. . Edwards sapien 3 valve. EuroIntervention 2012;8 Suppl Q:Q83–7. 10.4244/EIJV8SQA15 PubMed DOI

Mahajan S, Gupta R, Malik AH, et al. . Predictors of permanent pacemaker insertion after TAVR: a systematic review and updated meta-analysis. J Cardiovasc Electrophysiol 2021;32:1411–20. 10.1111/jce.14986 PubMed DOI

One-year Outcomes of Permanent Pacemaker Implantation after Transcatheter Aortic Valve Replacement: CONDUCT Registry: A Propensity Score-Matched Comparison

See more in PubMed

ClinicalTrials.gov
NCT03497611